Keywords: Biomarkers, Cancer, ITPP, EPRI, Immunotherapy, Radiosensitizer, Breast Cancer
Motivation: We showed previously that multispectral optoacoustic tomography (MSOT) measures oxygen saturation (%sO2) of intravascular hemoglobin which can indirectly evaluate the effect of a radiosensitizer, inositol tripyrophosphate (ITPP), on tumor oxygenation. Electron paramagnetic resonance imaging (EPRI) could serve as a more direct biomarker by measuring the extravascular, extracellular oxygen pressure (pO2) in pre-clinical tumor models.
Goal(s): Validate prior MSOT results showing decrease in hemoglobin saturation with ITPP.
Approach: Use EPRI to observe extracellular oxygenation before and after treatment with ITPP compared with vehicle control.
Results: Tumors treated with ITPP demonstrated lower extracellular oxygenation compared to pretreatment levels (p = 0.003).
Impact: An imaging biomarker to determine how much a radiosensitizer improves tumor pO2 would dramatically impact clinical care by potentially improving response to radiotherapy and immunotherapy. EPRI could evaluate the effect of a radiosensitizer allowing for more personalized treatment approaches.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords